Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.

Jia H, Wang Y, Morris CD, Jacques V, Gottesfeld JM, Rusche JR, Thomas EA.

PLoS One. 2016 Mar 31;11(3):e0152498. doi: 10.1371/journal.pone.0152498. eCollection 2016.

2.

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW.

Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.

3.

Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation.

Bieszczad KM, Bechay K, Rusche JR, Jacques V, Kudugunti S, Miao W, Weinberger NM, McGaugh JL, Wood MA.

J Neurosci. 2015 Sep 23;35(38):13124-32. doi: 10.1523/JNEUROSCI.0914-15.2015.

4.

DcpS is a transcript-specific modulator of RNA in mammalian cells.

Zhou M, Bail S, Plasterer HL, Rusche J, Kiledjian M.

RNA. 2015 Jul;21(7):1306-12. doi: 10.1261/rna.051573.115. Epub 2015 May 22.

5.

Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue.

Rumbaugh G, Sillivan SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, Kilgore M, Kudugunti S, Puthanveettil SV, Sweatt JD, Rusche J, Miller CA.

Neuropsychopharmacology. 2015 Sep;40(10):2307-16. doi: 10.1038/npp.2015.93. Epub 2015 Apr 3.

6.

Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia.

Soragni E, Chou CJ, Rusche JR, Gottesfeld JM.

Front Neurol. 2015 Mar 5;6:44. doi: 10.3389/fneur.2015.00044. eCollection 2015.

7.

The effect of sulforaphane on histone deacetylase activity in keratinocytes: Differences between in vitro and in vivo analyses.

Dickinson SE, Rusche JJ, Bec SL, Horn DJ, Janda J, Rim SH, Smith CL, Bowden GT.

Mol Carcinog. 2015 Nov;54(11):1513-20. doi: 10.1002/mc.22224. Epub 2014 Oct 12. Erratum in: Mol Carcinog. 2016 Jul;55(7):1210.

8.

Epigenetic therapy for Friedreich ataxia.

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR.

Ann Neurol. 2014 Oct;76(4):489-508. doi: 10.1002/ana.24260. Epub 2014 Sep 16.

9.

A novel chemopreventive mechanism for a traditional medicine: East Indian sandalwood oil induces autophagy and cell death in proliferating keratinocytes.

Dickinson SE, Olson ER, Levenson C, Janda J, Rusche JJ, Alberts DS, Bowden GT.

Arch Biochem Biophys. 2014 Sep 15;558:143-52. doi: 10.1016/j.abb.2014.06.021. Epub 2014 Jul 5.

10.
11.

Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression.

Bhaskara S, Jacques V, Rusche JR, Olson EN, Cairns BR, Chandrasekharan MB.

Epigenetics Chromatin. 2013 Aug 15;6(1):27. doi: 10.1186/1756-8935-6-27.

12.

Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.

Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper A, Jacques V, Rusche J, Eischen CM, McGirt LY, Hiebert SW.

PLoS One. 2013 Jul 22;8(7):e68915. doi: 10.1371/journal.pone.0068915. Print 2013.

13.

Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.

Gottesfeld JM, Rusche JR, Pandolfo M.

J Neurochem. 2013 Aug;126 Suppl 1:147-54. doi: 10.1111/jnc.12302. Review.

14.

The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.

Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacques V, Kiledjian M, Jarecki J, Rusche J, DiDonato CJ.

Hum Mol Genet. 2013 Oct 15;22(20):4084-101. doi: 10.1093/hmg/ddt258. Epub 2013 Jun 4.

15.

The DcpS inhibitor RG3039 improves motor function in SMA mice.

Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin MY, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko CP, Sumner CJ.

Hum Mol Genet. 2013 Oct 15;22(20):4074-83. doi: 10.1093/hmg/ddt257. Epub 2013 May 31.

16.

Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia.

Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR.

PLoS One. 2013 May 17;8(5):e63958. doi: 10.1371/journal.pone.0063958. Print 2013.

17.

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner.

Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, Rusche JR, Wood MA.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52. doi: 10.1073/pnas.1213364110. Epub 2013 Jan 7.

18.

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM.

Parkinsonism Relat Disord. 2013 Feb;19(2):260-4. doi: 10.1016/j.parkreldis.2012.07.001. Epub 2012 Aug 14.

PMID:
22901956
19.

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

Soragni E, Xu C, Plasterer HL, Jacques V, Rusche JR, Gottesfeld JM.

J Child Neurol. 2012 Sep;27(9):1164-73. doi: 10.1177/0883073812448533. Epub 2012 Jul 4. Review.

20.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

21.

A gene expression phenotype in lymphocytes from Friedreich ataxia patients.

Coppola G, Burnett R, Perlman S, Versano R, Gao F, Plasterer H, Rai M, Saccá F, Filla A, Lynch DR, Rusche JR, Gottesfeld JM, Pandolfo M, Geschwind DH.

Ann Neurol. 2011 Nov;70(5):790-804. doi: 10.1002/ana.22526.

22.

Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.

Xu C, Soragni E, Jacques V, Rusche JR, Gottesfeld JM.

Pharmaceuticals (Basel). 2011 Dec 14;4(12):1578-1590.

23.

Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.

Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR, Gottesfeld JM.

Methods Mol Biol. 2011;793:495-508. doi: 10.1007/978-1-61779-328-8_32.

24.

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.

Sandi C, Pinto RM, Al-Mahdawi S, Ezzatizadeh V, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pook MA.

Neurobiol Dis. 2011 Jun;42(3):496-505. doi: 10.1016/j.nbd.2011.02.016. Epub 2011 Mar 17.

25.

HDAC3 is a critical negative regulator of long-term memory formation.

McQuown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T, Mullican SE, Jones S, Rusche JR, Lazar MA, Wood MA.

J Neurosci. 2011 Jan 12;31(2):764-74. doi: 10.1523/JNEUROSCI.5052-10.2011.

26.

Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice.

Amante DJ, Kim J, Carreiro ST, Cooper AC, Jones SW, Li T, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Ferrante RJ, Rusche J.

Amyotroph Lateral Scler. 2010 Dec;11(6):520-30. doi: 10.3109/17482968.2010.491867. Epub 2010 Jun 22.

PMID:
20565334
27.

Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.

Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pandolfo M.

PLoS One. 2010 Jan 21;5(1):e8825. doi: 10.1371/journal.pone.0008825.

28.

Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.

Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, Rusche JR, Gottesfeld JM.

Chem Biol. 2009 Sep 25;16(9):980-9. doi: 10.1016/j.chembiol.2009.07.010.

29.

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ.

Neurology. 2008 Sep 16;71(12):917-24. doi: 10.1212/01.wnl.0000325915.00112.61.

PMID:
18794494
30.

Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.

Jensen JE, Daniels M, Haws C, Bolo NR, Lyoo IK, Yoon SJ, Cohen BM, Stoll AL, Rusche JR, Renshaw PF.

Exp Clin Psychopharmacol. 2008 Jun;16(3):199-206. doi: 10.1037/1064-1297.16.3.199.

PMID:
18540779
31.

Increased amygdala fMRI activation after secretin administration.

Yurgelun-Todd DA, Rogowska J, Gruber SA, Bogorodzki P, Simpson NS, Irvin RW, Jauregui KA, Strong RA, Rusche JR.

Exp Clin Psychopharmacol. 2008 Jun;16(3):191-8. doi: 10.1037/1064-1297.16.3.191.

PMID:
18540778
32.

The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents.

Sun D, Liu WJ, Guo K, Rusche JJ, Ebbinghaus S, Gokhale V, Hurley LH.

Mol Cancer Ther. 2008 Apr;7(4):880-9. doi: 10.1158/1535-7163.MCT-07-2119.

33.

Effects of uridine on kindling.

Zhao Q, Shatskikh T, Marolewski A, Rusche JR, Holmes GL.

Epilepsy Behav. 2008 Jul;13(1):47-51. doi: 10.1016/j.yebeh.2008.02.002. Epub 2008 Mar 5.

PMID:
18321784
34.

Stimulating resident research in a general surgery residency community program.

Lohr J, Smith JM, Welling R, Engel A, Hasselfeld K, Rusche J.

Curr Surg. 2006 Nov-Dec;63(6):426-34.

PMID:
17084772
35.

Lack of effect of secretin on kindling and seizures.

Zhao Q, Boismenu R, Rusche JR, Holmes GL.

Epilepsy Behav. 2006 Aug;9(1):46-50. Epub 2006 May 24.

PMID:
16723277
36.

Effects of uridine in models of epileptogenesis and seizures.

Zhao Q, Marolewski A, Rusche JR, Holmes GL.

Epilepsy Res. 2006 Jul;70(1):73-82. Epub 2006 Apr 18.

PMID:
16621451
38.

Partial reversal of phencyclidine-induced impairment of prepulse inhibition by secretin.

Myers KM, Goulet M, Rusche J, Boismenu R, Davis M.

Biol Psychiatry. 2005 Jul 1;58(1):67-73.

PMID:
15992525
39.

Level of education and patient opinion: significant differences in perceptions of health care.

Lewis CE, Woods SE, Lohr J, Poynter M, Engel AM, Rusche J.

Curr Surg. 2004 Sep-Oct;61(5):504-10.

PMID:
15475106
40.

Age-related and regional differences in secretin and secretin receptor mRNA levels in the rat brain.

Tay J, Goulet M, Rusche J, Boismenu R.

Neurosci Lett. 2004 Aug 12;366(2):176-81.

PMID:
15276242
41.

Tolerability of rofecoxib versus naproxen.

Rusche JM.

Ann Intern Med. 2004 Jun 15;140(12):1059; author reply 1060. No abstract available.

PMID:
15197028
42.

Inhibition of fear potentiated startle in rats following peripheral administration of secretin.

Myers K, Goulet M, Rusche J, Boismenu R, Davis M.

Psychopharmacology (Berl). 2004 Feb;172(1):94-9. Epub 2003 Oct 29.

PMID:
14586542
43.

Competency program development across a merged healthcare network.

Rusche JD, Besuner P, Partusch SK, Berning PA.

J Nurses Staff Dev. 2001 Sep-Oct;17(5):234-40; quiz 241-2.

PMID:
12759992
44.

A secretin i.v. infusion activates gene expression in the central amygdala of rats.

Goulet M, Shiromani PJ, Ware CM, Strong RA, Boismenu R, Rusche JR.

Neuroscience. 2003;118(4):881-8.

PMID:
12732234
45.

Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse.

Banks WA, Goulet M, Rusche JR, Niehoff ML, Boismenu R.

J Pharmacol Exp Ther. 2002 Sep;302(3):1062-9.

PMID:
12183664
46.

Unique Structures Generated by Ugi 3CC Reactions Using Bifunctional Starting Materials Containing Aldehyde and Carboxylic Acid.

Zhang J, Jacobson A, Rusche JR, Herlihy W.

J Org Chem. 1999 Feb 5;64(3):1074-1076. No abstract available.

PMID:
11674195
47.

Identification of inhibitors of heparin-growth factor interactions from combinatorial libraries of four-component condensation reactions.

Zhang J, Riverst G, Zhu Y, Jacobson A, Peyers J, Grundstrom G, Burch P, Hussein S, Marolewski A, Herlihy W, Rusche J.

Bioorg Med Chem. 2001 Apr;9(4):825-36.

PMID:
11354665
48.

CTLA4Ig-induced linked regulation of allogeneic T cell responses.

Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC.

Transplant Proc. 2001 Feb-Mar;33(1-2):88-9. No abstract available.

PMID:
11266718
49.

CTLA4Ig and donor-specific transfusion prolongs cardiac allograft survival in the miniature swine.

Lee RS, Rusche JR, Cheatham LA, Yamada K, Houser SL, Maloney ME, Amoah HC, Mezrich JB, Sayegh MH, Madsen JC.

J Heart Lung Transplant. 2001 Feb;20(2):150. No abstract available.

PMID:
11250209
50.

CTLA4Ig-induced linked regulation of allogeneic T cell responses.

Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC.

J Immunol. 2001 Feb 1;166(3):1572-82.

Supplemental Content

Loading ...
Support Center